Monograph Details
|
|
Central Nervous System
> Restless legs syndrome
|
|
REQUIP |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Dopamine agonist (non-ergot). |
| Generic Name |
|
Ropinirole (as HCl) 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg; tabs. |
| Also |
|
• REQUIP XL
|
| Indications |
|
Restless legs syndrome. |
| Children |
|
Not recommended. |
| Adults |
|
Titrate gradually. Taking with food may reduce nausea. Take once-daily 1–3 hrs before bedtime. Initially 0.25mg on Days 1 & 2, then 0.5mg on days 3–7, increase by 0.5mg/day at 1-week intervals to 3mg then may increase to 4mg after 1 week; max 4mg/day. |
| Precautions |
|
See literature. Consider discontinuing if excessive daytime sleepiness or if sudden onset of sleep during daily activities occurs. Monitor for drowsiness or sleepiness, and for orthostatic hypotension. Hypertension. Changes in heart rate. Psychotic disorders. Sleep disorders. Severe renal or hepatic impairment. Severe cardiovascular disease. Avoid abrupt cessation (withdraw over 1 week). Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Alcohol, other CNS depressants may be potentiated. Potentiated by ciprofloxacin, possibly other CYP1A2 inhibitors. May be antagonized by dopamine antagonists (eg, phenothiazines, butyrophenones, metoclopramide). Adjust ropinirole dose if estrogens are added or discontinued. Monitor with drugs that induce CYP1A2 (eg, cigarette smoke). |
| Adverse Reactions |
|
Nausea, vomiting, somnolence, dizziness, fatigue, others. |
| How Supplied |
Tabs—100
Starter kit (0.25mg x 2 tabs, 0.5mg x 5 tabs, 1mg x 7 tabs)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
